CAR-NK-CD19 cells
/ Beijing Boren Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 08, 2022
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies
(clinicaltrials.gov)
- P1 | N=15 | Recruiting | Sponsor: Beijing Boren Hospital
New P1 trial • Acute Lymphocytic Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
1 to 1
Of
1
Go to page
1